A small Massachusetts General Hospital pilot found that 47% of adults with ADHD met response criteria after up to 12 weeks of magnesium L-threonate, the so-called brain-penetrating magnesium. The study also reported significant improvements in symptom ratings and a measure of cognitive shifting. But the trial had just 15 participants, no placebo group and funding tied to the compound's developer. Here is why threonate gets the hype, what the results really show, and how to think about it without getting ahead of the evidence.
This page is available in